Pharmaceutical Accountability Foundation

PAF Intro The Pharmaceutical Accountability Foundation

STRIVING FOR EQUAL ACCESS TO MEDICINES AND MEDICAL TECHNOLOGIES Covid-19 arrow_forward_ios Case studies arrow_forward_ios
Humira case Our latest case: Humira

Explainer arrow_forward_ios Statement arrow_forward_ios
Legal Guidelines Legal Guidelines


Access to medicines is a human right

At Pharmaceutical Accountability Foundation, we believe the pharmaceutical industry has to be held accountable when they limit needed access by raising prices to unsustainable levels in pursuit of unfair profits. We therefore investigate cases of pharmaceutical company abuse of market exclusivity rights to keep prices high at the expense of public health. We then work to inform the public, or take legal action if necessary.


Why is medical technology so very expensive? There are many issues in the way we currently incentivise innovation.


There are several legal and policy solutions to stop misconduct, high prices, and limited access to medicines.


Examples of excessive pricing we have marked for investigation, or find illustrative of systemic challenges.

Recent News

Martina Liccardo’s take on the role of the European Medicine Agency in Leadiant’s price misuse with CDCA

As an international student I have always sought out opportunities to meet local people and to broaden my personal and professional network. When provided with the...

Pharma companies mostly fail to meet human rights principles, but a few show promise

The new Fair Pharma Scorecard – developed by the Pharmaceutical Accountability Foundation – shows that 19 out of 26 pharmaceutical companies scored poorly on their...

How Fair is Pharma?

The Pharmaceutical Accountability Foundation invites you to join our event presenting the Fair Pharma Scorecard, on Thursday 30 June 4PM CET.  Please register here. Fair Pharma Scorecard To...

After Netherlands and Israel, now Italy: Leadiant fined for excessive price

Bergeijk, June 2, 2022 The Italian Competition Authority (ICA) decided on 31 May that pharmaceutical company Leadiant has charged the Italian National Health Service excessive prices...

Recent Tweets

#BREAKING|🤝🏽@MedsPatentPool and @SHIONOGI_JP sign a licence agreement for a 💊#COVID19 oral antiviral treatment candidate to increase access in low- and middle-income countries.

Access our joint #PressRelease 👉🏽

#HealthForAll #Access2Meds #PublicHealth

Last week at the #WTOPublicForum, we brought together a panel of experts to answer essential questions about the law & policy tools needed to face current and future #globalhealth challenges. A recording of the event is available here:

Advocates Mount New Initiative for WTO to Recognize ‘Public Goods’ in Trade Agreements – from Medicines to Forests

Load More